Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2013 3
2014 3
2015 3
2017 1
2018 2
2019 2
2020 1
2021 1
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials.
Gbadamosi MO, Shastri VM, Elsayed AH, Ries R, Olabige O, Nguyen NHK, De Jesus A, Wang YC, Dang A, Hirsch BA, Alonzo TA, Gamis A, Meshinchi S, Lamba JK. Gbadamosi MO, et al. Leukemia. 2022 Aug;36(8):2022-2031. doi: 10.1038/s41375-022-01622-0. Epub 2022 Jun 10. Leukemia. 2022. PMID: 35688939 Free PMC article.
ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial.
Rafiee R, Chauhan L, Alonzo TA, Wang YC, Elmasry A, Loken MR, Pollard J, Aplenc R, Raimondi S, Hirsch BA, Bernstein ID, Gamis AS, Meshinchi S, Lamba JK. Rafiee R, et al. Blood Cancer J. 2019 May 21;9(6):51. doi: 10.1038/s41408-019-0211-y. Blood Cancer J. 2019. PMID: 31113932 Free PMC article. Clinical Trial.
CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agents.
Papageorgiou I, Loken MR, Brodersen LE, Gbadamosi M, Uy GL, Meshinchi S, Lamba JK. Papageorgiou I, et al. Leuk Lymphoma. 2019 Sep;60(9):2287-2290. doi: 10.1080/10428194.2019.1569232. Epub 2019 Feb 5. Leuk Lymphoma. 2019. PMID: 30721105 Free PMC article. No abstract available.
CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.
Lamba JK, Chauhan L, Shin M, Loken MR, Pollard JA, Wang YC, Ries RE, Aplenc R, Hirsch BA, Raimondi SC, Walter RB, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S. Lamba JK, et al. J Clin Oncol. 2017 Aug 10;35(23):2674-2682. doi: 10.1200/JCO.2016.71.2513. Epub 2017 Jun 23. J Clin Oncol. 2017. PMID: 28644774 Free PMC article. Clinical Trial.
19 results